Şunu aradınız:: interferoonide (Estonca - İngilizce)

kombineeritud ravi beeta- interferoonide või glatirameeratsetaadiga.
combination with beta-interferons or glatiramer acetate.

mitmekordse annuse järgselt tekib immunoreaktiivsete interferoonide kumulatsioon.
upon multiple dosing, there is an accumulation of immunoreactive interferons.

seoses interferoonide kasutamisega on esinenud muutusi laboratoorsetes analüüsides.
laboratory abnormalities are associated with the use of interferons.

pegasysi toimeaine alfa-2a-peginterferoon kuulub interferoonide rühma.
the active substance in pegasys, peginterferon alfa-2a, belongs to the group ‘interferons’.

avonexi toimeaine beeta-1a-interferoon kuulub interferoonide rühma.
the active substance in avonex, interferon beta-1a, belongs to the group ‘interferons’.

eristatakse kolme peamist interferoonide rühma: alfa, beeta ja gamma.
three major forms of interferons have been distinguished: alpha, beta, and gamma.

interferoonide rakuline aktiivsus põhineb nende seostumisel spetsiifiliste membraaniretseptoritega rakkude pinnal.
interferons exert their cellular activities by binding to specific membrane receptors on the cell surface.

70 interferoonide rakuline aktiivsus põhineb nende seostumisel spetsiifiliste membraaniretseptoritega rakkude pinnal.
ori interferons exert their cellular activities by binding to specific membrane receptors on the cell surface.

naha kahjustus alfa- interferoonide kasutamist on seostatud psoriaasi ja sarkoidoosi ägenemise või esilekutsumisega.
skin disorder use of alpha interferons has been associated with exacerbation or provocation of psoriasis and sarcoidosis.

nagu ka teiste interferoonide puhul, täheldati neutraliseerivate antikehade suuremat esinemissagedust kroonilise hepatiit b puhul.
as with other interferons, a higher incidence of neutralising antibodies was seen in chronic hepatitis b.

inimestel ja loomadel on kirjeldatud maksa tsütokroom p450-st sõltuvate ensüümide aktiivsuse vähenemist interferoonide toimel.
interferons have been reported to reduce the activity of hepatic cytochrome p450-dependent enzymes in humans and animals.

arvestades aga teiste alfa- või beeta-interferoonide uuringute tulemustega, ei saa tõusnud abordiriski välistada.
based on observations with other alpha and beta interferons, an increased risk of abortions cannot be excluded.

sarnaseid reproduktiivsust mõjutavaid annusest sõltuvaid toimeid on täheldatud ka teiste alfa- ja beeta-interferoonide vormidega.
similar reproductive dose-related effects have also been observed with other forms of alpha and beta interferons.

nagu teistegi beeta- interferoonide korral on extavia-ravi saavatel patsientidel teatatud maksakahjustuste juhtudest, sealhulgas maksapuudulikkusest.
as for other beta interferons, cases of severe hepatic injury, including hepatic failure, have been reported in patients treated with extavia.

interferoonide kasutamist on seostatud isutuse, pearingluse, ärevuse, südame rütmihäirete, vasodilatatsiooni ja palpitatsioonide, menorraagia ja metrorraagia tekkega.
the administration of interferons has been associated with anorexia, dizziness, anxiety, arrhythmias, vasodilation and palpitation, menorrhagia and metrorrhagia.

nagu teistegi beeta-interferoonide korral, teatati ka betaferon’iga ravitud patsientidel harva maksakahjustustest, sealhulgas maksapuudulikkuse juhtudest.
as for other beta interferons, severe hepatic injury, including cases of hepatic failure, has been reported rarely in patients treated with betaferon.